Help

No. Access to specimen results are restricted by user role and the parameters provided on the user registration form by the authorized company representative. 

The LabCorp Corporate Solutions Web Tools Donor Registration feature enables the user to create a drug screen test order record that may be retrieved by the specimen collector in Web COC. Donor Registration assists employers in assuring that company drug testing deadlines are met, since the user may set a donor registration expiration date. Donor Registration enables the user to elect to receive email notification of each specimen collection completion or donor no-show. 

Generally within one business day from time of receipt. 

Complete the applicable LabCorp Corporate Solutions user registration form. Indicate on the user registration form that you are removing a user’s access. Submit completed and signed user registration forms to LabCorp occupational testing services by faxing to 919-481-5444 or emailing [email protected]. 

Yes. Labcorp Corporate Solutions Web Tools users with authorized access to view laboratory-scanned COC images may print or save the PDF. 

Simply stated, screening and confirmation testing are performed using different testing methodologies that have different specificity and sensitivity. The immunoassay tests used to perform initial drug screening are designed to detect a wide range of chemically similar compounds that react with the antibodies which are at the core of the chemistry making up the tests. The combined cross-reactivity of compounds in the drug class may elicit a positive response, even though an individual metabolite may be present below the initial test cutoff. When performing confirmation testing by GC/MS or LC/MS/MS, one or more specific metabolites can be identified, quantified and reported using the applicable confirmation cutoff for a positive test result. 

Nanograms per milliliter, abbreviated ng/mL, is the unit of measure most commonly used to express drug testing cut-off levels and quantitative test results in urine and oral fluid. A nanogram is 10-9 grams. 

Specimen validity testing (SVT) is performed on a urine drug screen specimen to detect substitution, adulteration, or dilution. See the Drugs of Abuse Reference Guide for additional information on SVT. Use of a Medical Review Officer is recommended to evaluate out of range SVT results.

• Substitution - Submission of a specimen that is not characteristic of human urine. Typically, this may be water or water with salt in it and is identified by extreme creatinine and specific gravity results.
• Adulteration - Adding a substance to a specimen after it has been collected. The product added is designed to mask the presence of, or chemically destroy, the drug or drug metabolite that the specimen may contain. An adulterant product may be added with the intention of adversely affecting the testing reagents.
• Dilution - Result of ingestion of large amounts of water typically just before urine donation or as a result of physiological conditions. If drug/metabolites are diluted to a concentration below the initial test cutoff, a dilute urine may result in a false negative.

No, specimen validity testing is performed simultaneously with the initial drug screens. Depending upon the drug screen and the specimen validity results, the laboratory will release (1) both the drug screen and the specimen validity test results, (2) the specimen validity test results only, or (3) the drug screen results only. 

MDMA is a synthetic amphetamine structure and does cross-react with existing amphetamine immunoassays. However, the cross-reactivity of MDMA in amphetamine assays is generally less than 100%, so it may not be picked up at commonly-used testing cut-offs. To enable detection of MDMA following normal exposures, LabCorp uses reagents developed specifically for MDMA detection.²